Skip to main content

Table 3 Odds ratio (OR) and 95% confidence interval (CI) adjusted for hormone receptor expression and tumor grading according to cytokines levels in HER+ and HER- patients

From: A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies

 

Cytokines level quartiles1

 
 

1-low

2

3

4-high

Ptrend

IL-1b

     

N. pos/neg2

4/11

5/10

5/10

11/5

 

OR (95% CI)

13

6.3 (0.7-53.2)

33.6 (2.3-494.6)

55.4 (4.1-746.0)

0.002

IL-2

     

N. pos/neg2

3/12

6/9

6/10

10/5

 

OR (95% CI)

13

15.7 (1.6-150.5)

10.3 (1.2-92.4)

31.8 (3.5-289.6)

0.004

IL-6

     

N. pos/neg2

2/15

5/9

7/8

11/4

 

OR (95% CI)

13

3.8 (0.5-31.0)

8.2 (1.0-65.4)

21.9 (2.6-185.8)

0.004

IL-8

     

N. pos/neg2

2/14

6/9

8/7

9/6

 

OR (95% CI)

13

3.7 (0.5-26.0)

5.6 (0.7-42.3)

11.7 (1.4-95.5)

0.02

IL-10

     

N. pos/neg2

6/11

3/9

5/10

11/4

 

OR (95% CI)

13

0.3 (0.04-2.6)

1.6 (0.2-12.1)

9.6 (1.5-59.0)

0.02

  1. 1Quartiles were: IL-1b: ≤0.5/0.6-1.7/1.8-4.2/≥4.3; IL-2: ≤2.2/2.3-5.8/5.9-15.8/≥15.9; IL-6: ≤1.6/1.7-3.4/3.5-6.5/≥6.6; IL-8: ≤1.7/1.8-3.7/3.8-6.2/≥6.3; IL-10: ≤0.4/0.5-1.4/1.5-3.3/≥3.4 pg/ml.
  2. 2 pos, HER2+; neg, HER2-;
  3. 3 Reference category.
  4. HER-2, human epidermal growth factor receptor-2; IL, interleukin.